Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

NCT05899673 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05899673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05899673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 8, 2023
Completion date
May 2, 2033
Enrollment
31 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

alpha1-antitrypsin deficiency